Jiannjia Robotics Completes Enrollment of Pivotal Clinical Trial for Knee Application, Advancing China's First Hip-Knee Multi-Application Orthopedic Surgical Robot Platform

Recently, the ARTHROBOT joint surgery robot, independently developed by Jianjia Robotics, successfully completed all patient enrollment surgeries for its definitive clinical trial in knee joint applications. This marks the first joint surgery robot among similar domestic products to complete clinical trials across multiple surgical applications, representing a significant milestone for Chinese-made joint surgery robots.

It is reported that five top-tier medical institutions in China, along with renowned joint surgery experts and their teams, participated in this clinical trial. These include Professor Wang Kunzheng and his team from the Second Affiliated Hospital of Xi’an Jiaotong University; Professor Yan Shigui and his team from the Second Affiliated Hospital of Zhejiang University School of Medicine; Professor Tian Hua and his team from Peking University Third Hospital; Professor Shi Zhanjun and his team from Nanfang Hospital, Southern Medical University; and Professor Qi Rongqian and his team from Shanghai Changzheng Hospital. Following the completion of patient enrollment surgeries for the knee joint clinical trial project, Professor Wang Kunzheng, the lead investigator, stated, “In recent years, surgical robots have been rapidly adopted across China. The precision and efficiency of domestically produced surgical robots are impressive. We hope the company will continue to lead and drive innovation, bringing more intelligent orthopedic products to clinicians.”

With the completion of patient enrollment in this confirmatory clinical trial, the precision and efficacy of ARTHROBOT have been further validated, marking that China’s robotic products and therapeutic technologies for joint replacement surgery are at the forefront globally.

According to statistical data from Frost & Sullivan, the number of hip replacement surgeries in China was 285,000 in 2016, and the number of knee replacement surgeries was 171,000. By 2020, the number of hip replacement surgeries in China had risen to 715,000, while knee replacement surgeries reached 465,000. It is projected that by 2021, the number of hip replacement surgeries will reach 887,000, and knee replacement surgeries will amount to 577,000, representing a compound annual growth rate (CAGR) of 24%. Previously, industry analysts pointed out that the significant price reduction of artificial joint consumables following centralized procurement would directly ignite the orthopedic joint surgery market, leading to a substantial increase in the volume of artificial joint replacement surgeries.

However, traditional orthopedic surgeries, due to their heavy reliance on surgical equipment and surgeons’ clinical experience, suffer from limitations such as inconsistent operational precision and difficulties in popularizing complex surgical techniques. Furthermore, the steep learning curve for orthopedic surgeons consumes significant time resources for physicians and clinical resources for hospitals, thereby restricting talent development. These factors also hinder hospitals from scaling up orthopedic surgical services. With rising patient expectations for surgical quality, substantial price reductions in joint implants, increased demand for capacity building in primary care hospitals, and the widespread adoption of concepts related to precision medicine and intelligent surgical procedures, robotic surgery has become an inevitable trend in joint replacement operations. Its superior precision, safety, and efficiency address the pain points of traditional orthopedic surgery, making it a key approach for enhancing surgical quality and achieving precision medicine in the future.

Founded in 2018, Keyijia Robotics has rapidly emerged as a leading domestic platform enterprise for hard-tissue surgical robots, leveraging its team’s extensive prior experience in the field, outstanding integration of medicine and engineering, and strong execution capabilities. The company’s hip replacement surgical robot is the first “total hip replacement surgical robot” product in China to enter the NMPA’s Special Review Procedure for Innovative Medical Devices and is on the verge of obtaining regulatory approval. As Keyijia Robotics’ second product, its knee replacement surgical robot completed enrollment for all clinical trials in less than a year. The company is well-positioned to seize the first-mover advantage in the joint replacement surgical robot market and become a domestic market pioneer in this industry.